Avancées et synthèse des derniers congrès : ASCO-GU, EAU, AUA, ASCO concernant la prise en charge médicale du cancer du rein localement avancé ou métastatique

25 mars 2010

Auteurs : J.-J. Patard, B. Escudier, P. Paparel, Y. Neuzillet, J.-A. Long, H. Baumert, J.-M. Correas, H. Lang, L. Poissonnier, N. Rioux-Leclercq, M. Soulié, et le Comité de Cancérologie de l'Association Française d'Urologie (CCAFU)
Référence : Prog Urol, 2010, 20, S11, suppl. S1




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 2009 ;  27 : 3584-3590 [cross-ref]
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 2009 ;  27 : 3312-3318 [cross-ref]
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 ;  356 : 2271-2281 [cross-ref]
Rini B.I., Halabi S., Rosenberg J., Stadler W.M., Vaena D.A., Atkins J.N., et al. Bévacizumab plus interferon-alpha versus interferonalpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 J Clin Oncol (Meeting Abstracts) 2009 ;  27 : LBA5019.
Escudier B.J., Bellmunt J., Negrier S., Melichar B., Bracarda S., Ravaud A., et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bévacizumab (BEV) + interferon-{alpha}2a (IFN) in metastatic renal cell carcinoma (mRCC) J Clin Oncol (Meeting Abstracts) 2009 ;  27 : 5020
Szczylik C., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) J Clin Oncol (Meeting Abstracts) 2008 ;  26 : 5124
Kutikov A., Uzzo R.G., Egleston B.L., Blakely S.A., Iffrig K., Chen D.Y., et al. Rapid progression is the primary reason patients fail to receive systemic therapy following cytoreductive nephrectomy J Urol (AUA annual meeting) 2009 ;  181 : Abstract 1390.
Patil S., Figlin R.A., Hutson T.E., Michaelson M.D., Negrier S., Kim S.T., et al. Prognostic factors for overall survival with sunitinib as firstline therapy in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol (Meeting Abstracts) 2009 ;  27 : Abstract 5042, 5244.
Heng D.Y., Xie W., Regan M.M., Cheng T., North S., Knox J.J., et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study J Clin Oncol (Meeting Abstracts) 2009 ;  27 : abstract 5041, 5244.
Sternberg C.N., Szczylik C., Lee E., Salman P.V., Mardiak J., Davis I.D., et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) J Clin Oncol (Meeting Abstracts) 2009 ;  27 : 5021






© 2010 
Elsevier Masson SAS. Tous droits réservés.